ACGT Investigator Award in Cell and Gene Therapy for Solid Tumor Cancers- LOI/Abstract
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: Inquire with unit
Memorial Deadline: RIS Review not required for LOI
External Deadline: Friday 15th, May 2026
Description
Alliance for Cancer Gene Therapy, Inc. (ACGT) funds breakthrough research that is transforming cancer treatment through cell and gene therapy. This ACGT grant award is for those conducting translational cell and gene therapy research specifically in solid tumor cancers. Cell and gene therapy for solid tumors poses major challenges driven by antigen heterogeneity, physical exclusion, immunosuppressive microenvironments, genomic instability, and safety limitations. This RFA seeks innovative, translational cell and gene therapy strategies that directly address these barriers.
Proposed approaches should demonstrate the capacity to:
– Overcome antigen escape through multi-targeted designs that broaden patient populations and account for heterogeneity and resistance due to antigen loss.
– Enhance trafficking, infiltration, and persistence within solid tumor sites.
– Resist or reprogram the immunosuppressive tumor microenvironment.
– Incorporate built-in safety and controllability mechanisms suitable for clinical translation. Successful proposals will integrate these elements to enable durable, precise, and scalable therapeutic impact in solid tumors.
- Abstract Deadline: May 15, 2026, at 11 am (EST)
- Deadline for Invited Applications: September 1, 2026, at 11 am (EST)
- For more information and to access the RFA, please visit the ACGT website.